Sugi Predict

Sugi Predict / Compounds / SCHEMBL2116180

SCHEMBL2116180

SCHEMBL2116180

Cc1cc(=O)n(C)cc1Br

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BRD4 O60885 3/20 0.36
▸ ATAD2 Q6PL18 2/20 0.36
▸ BAZ2B Q9UIF8 1/20 0.35
▸ BAZ2A Q9UIF9 1/20 0.35
▸ KDM4E B2RXH2 2/20 0.34
▸ NQO2 P16083 2/20 0.34
▸ POLB P06746 2/20 0.33
▸ BCHE P06276 1/20 0.33
▸ CES1 P23141 1/20 0.33
▸ L3MBTL1 Q9Y468 1/20 0.33
▸ LMNA P02545 1/20 0.33
▸ ALKBH5 Q6P6C2 1/20 0.33
▸ HPGD P15428 1/20 0.32
▸ NPSR1 Q6W5P4 1/20 0.32
▸ HSD17B10 Q99714 1/20 0.32
▸ CREBBP Q92793 2/20 0.32
▸ MEN1 O00255 1/20 0.32
▸ KMT2A Q03164 1/20 0.32
▸ CYP19A1 P11511 2/20 0.32
▸ MAP2K2 P36507 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13481160 0.78 ATAD2 (0.39) BRD4ATAD2BAZ2BBAZ2AKDM4E
SCHEMBL15535707 0.77 ATAD2 (0.45) BRD4ATAD2BAZ2BBAZ2AKDM4E
SCHEMBL15550000 0.76 BAZ2B (0.45) ATAD2BAZ2BBAZ2ACREBBPMAP2K2
SCHEMBL21904988 0.76 ATAD2 (0.35) ATAD2BAZ2BBAZ2AKDM4EL3MBTL1
SCHEMBL20157933 0.76 MAP2K1 (0.39) BRD4ATAD2BAZ2BBAZ2ACREBBP
SCHEMBL24837083 0.76 ATAD2 (0.35) ATAD2BAZ2BBAZ2AMAP2K2MAP2K1
SCHEMBL20157278 0.75 KDM4E (0.40) BRD4ATAD2KDM4ELMNACREBBP
SCHEMBL20519227 0.74 BAZ2B (0.37) BRD4ATAD2BAZ2BBAZ2AMAP2K2
SCHEMBL6239638 0.73 BRD4 (0.36) BRD4ATAD2BAZ2BBAZ2AKDM4E
SCHEMBL12172358 0.73 MAP2K2 (0.39) BRD4ATAD2BAZ2BBAZ2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2026090477-A1 HELICASE INHIBITORS AND USES THEREOF KIMIA THERAPEUTICS, INC. (US) 2026-04-30 — — WO disclosed
EP-4720040-A1 SULFONAMIDE COMPOUNDS BENEFICIAL IN NEUROPROTECTIVE TREATMENT Lario Therapeutics Limited (GB) 2026-04-08 — — EP disclosed
EP-4134364-B1 BROMODOMAIN INHIBITORS CELGENE QUANTICEL RES INC (US) 2025-07-30 — — EP disclosed
US-20240425478-A1 CYCLOPENTYLPYRAZOLE CDK2 INHIBITORS GENENTECH INC (US) 2024-12-26 — — US disclosed
WO-2024246522-A1 SULFONAMIDE COMPOUNDS BENEFICIAL IN NEUROPROTECTIVE TREATMENT LARIO THERAPEUTICS LIMITED (GB) 2024-12-05 — — WO disclosed
US-20240182490-A1 BROMODOMAIN INHIBITORS CELGENE QUANTICEL RESEARCH, INC. (US) 2024-06-06 — — US disclosed
US-11884680-B2 Bromodomain inhibitors CELGENE QUANTICEL RESEARCH, INC. (US) 2024-01-30 — — US disclosed
CN-116547275-A IL-17A modulators 赛诺菲 2023-08-04 — — CN disclosed
US-20230227427-A1 IL-17A MODULATORS SANOFI (FR) 2023-07-20 — — US disclosed
EP-4157827-A1 IL-17A MODULATORS SANOFI (FR) 2023-04-05 — — EP disclosed
US-20150111885-A1 BROMODOMAIN INHIBITORS CELGENE QUANTICEL RESEARCH, INC. 2015-04-23 — — US disclosed
US-20150111885-A1 BROMODOMAIN INHIBITORS CELGENE QUANTICEL RESEARCH, INC. 2015-04-23 — — US disclosed
US-20150005232-A1 INDAZOLE DERIVATIVES TAKEDA PHARMACEUTICAL COMPANY LIMITED (US) 2015-01-01 — — US disclosed
US-20150005232-A1 INDAZOLE DERIVATIVES TAKEDA PHARMACEUTICAL COMPANY LIMITED (US) 2015-01-01 — — US disclosed
US-20150005232-A1 INDAZOLE DERIVATIVES TAKEDA PHARMACEUTICAL COMPANY LIMITED (US) 2015-01-01 — — US disclosed
WO-2013130855-A1 INDAZOLE DERIVATIVES TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-09-06 — — WO disclosed
WO-2013130855-A1 INDAZOLE DERIVATIVES TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-09-06 — — WO disclosed
US-8158652-B2 1-Difluoromethyl-5-{4-[3-(1-piperidinyl)propoxy]phenyl}-2(1H)-pyridone; compounds act as histamine-H3 receptor antagonistic substances or inverse-agonistic substances; useful as preventives or remedies for various circular system diseases, nervous system diseases, metabolic system diseases MSD K.K. (JP) 2012-04-17 — — US disclosed
US-20080269287-A1 Substituted Pyridone Derivative MSD K.K. (JP) 2008-10-30 — — US disclosed
EP-1820797-A1 SUBSTITUTED PYRIDONE DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. (JP) 2007-08-22 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240425478-A1 CYCLOPENTYLPYRAZOLE CDK2 INHIBITORS CDK2, CCNI, CDK20 BRD4 1123/4885ATAD2 3579/4885BAZ2B 1502/4885
US-20230227427-A1 IL-17A MODULATORS IL17A, IL2, IL15 BRD4 1372/4885ATAD2 4256/4885BAZ2B 1435/4885
US-20150005232-A1 INDAZOLE DERIVATIVES GPR119, INSR, INSRR BRD4 635/4885ATAD2 362/4885BAZ2B 2535/4885
US-20240182490-A1 BROMODOMAIN INHIBITORS BRD3, EP300, BRPF3 BRD4 5/4885ATAD2 161/4885BAZ2B 7/4885
US-20080269287-A1 Substituted Pyridone Derivative HRH3, HRH4, HRH1 BRD4 492/4885ATAD2 1406/4885BAZ2B 1244/4885
US-20150111885-A1 BROMODOMAIN INHIBITORS BRD3, EP300, BRPF3 BRD4 5/4885ATAD2 161/4885BAZ2B 7/4885
US-11884680-B2 Bromodomain inhibitors BRD3, EP300, BRPF3 BRD4 5/4885ATAD2 161/4885BAZ2B 7/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.